Ipsen and Marengo Therapeutics Inc, a clinical-stage biotech company, announced today the expansion of their ongoing oncology research partnership, to include TriStar, Marengo’s next-generation, precision T cell engager (TCE) technology.
French biopharma Ipsen and US-based Marengo Therapeutics have formed a strategic partnership that aims to advance two of Marengo’s preclinical immuno-oncology candidates.
French pharma Ipsen has entered into exclusive negotiations for the sale of its global consumer healthcare business to compatriot firm Mayoly Spindler. The move, said Ipsen, is a major step forward in its strategy to sharpen its focus on specialty care.
